India, October 8, 2026: Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP. The Hindu reported the development.

According to The Hindu, Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.

The same account adds: Unlock these with Subscription Health Matters Ramya Kannan writes to you on getting to good health, and staying there The Hindu On Books Books of the week, reviews, excerpts, new titles and features.

Image used for representational purposes only.

| Photo Credit: Getty Images/iStockphoto In a bid to make cancer treatment more affordable and reduce patients’ out-of-pocket expenditure, the Union government has decided to cap trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs .

The measure will cover branded and generic drugs , domestically manufactured and imported medicines, and patented and non-patented products.

An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be brought under the measure.

The story is filed under Health. Rajasthani News is carrying the opening of that report and will revise this copy only when a later account confirms something new.